Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting preclinical antibodies from Regeneron
Covered in this story
What has happened since
- Sanofi is up 0.7% since this was published, 19 days ago.
- Regeneron Pharmaceuticals is up 7.9% since this was published, 19 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $SAN.PA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Sanofi →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.